Search results

524 results

View results as:
Number of results to display per page
Book
1 online resource. Digital: text file; PDF.
Book
1 online resource
  • Part I: General Aspects. Serendipitous Target-Based Drug Discoveries / János Fischer, David P Rotella
  • Drug Discoveries and Molecular Mechanism of Action / David C Swinney
  • Part II: Drug Class. Insulin Analogs - Improving the Therapy of Diabetes / John M Beals
  • Part III: Case Histories. The Discovery of Stendra (Avanafil) for the Treatment of Erectile Dysfunction / Koichiro Yamada, Toshiaki Sakamoto, Kenji Omori, Kohei Kikkawa
  • Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes / William N Washburn
  • Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy / Hisashi Shinkai
  • Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus / Matthias Eckhardt, Thomas Klein, Herbert Nar, Sandra Thiemann
  • The Discovery of Alimta (Pemetrexed) / Edward C Taylor
  • Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy / Shigeki Hibi
  • Discovery and Development of Telaprevir (Incivek): A Protease Inhibitor to Treat Hepatitis C Infection / Bhisetti G Rao, Mark Murcko, Mark J Tebbe, Ann D Kwong
  • Antibody-Drug Conjugates: Design and Development of Trastuzumab Emtansine (T-DM1) / Sandhya Girish, Gail D Lewis Phillips, Fredric S Jacobson, Jagath R Junutula, Ellie Guardino.
  • Part I: General Aspects. Serendipitous Target-Based Drug Discoveries / János Fischer, David P Rotella
  • Drug Discoveries and Molecular Mechanism of Action / David C Swinney
  • Part II: Drug Class. Insulin Analogs - Improving the Therapy of Diabetes / John M Beals
  • Part III: Case Histories. The Discovery of Stendra (Avanafil) for the Treatment of Erectile Dysfunction / Koichiro Yamada, Toshiaki Sakamoto, Kenji Omori, Kohei Kikkawa
  • Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes / William N Washburn
  • Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy / Hisashi Shinkai
  • Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus / Matthias Eckhardt, Thomas Klein, Herbert Nar, Sandra Thiemann
  • The Discovery of Alimta (Pemetrexed) / Edward C Taylor
  • Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy / Shigeki Hibi
  • Discovery and Development of Telaprevir (Incivek): A Protease Inhibitor to Treat Hepatitis C Infection / Bhisetti G Rao, Mark Murcko, Mark J Tebbe, Ann D Kwong
  • Antibody-Drug Conjugates: Design and Development of Trastuzumab Emtansine (T-DM1) / Sandhya Girish, Gail D Lewis Phillips, Fredric S Jacobson, Jagath R Junutula, Ellie Guardino.
Book
1 online resource (x, 350 pages).
Book
1 online resource (xiii, 550 pages) : illustrations (some color).
  • 1 Hybrid QM/MM Methods: Treating Electronic Phenomena in Very Large Molecular Systems
  • 2 Structure, Thermodynamics and Energetics of Drug-DNA Interactions: Computer Modeling and Experiment
  • 3 Formation of DNA Lesions, Its Prevention and Repair
  • 4 DNA dependent DNA Polymerases as Targets for Low-Weight Molecular Inhibitors: State of Art and Prospects of Rational Design
  • 5 Molecular structures, relative stability, and proton affinities of nucleotides: Broad view and novel findings
  • 6 Quantum Chemical Approaches in Modeling the Structure of Quadruplex DNA and Its Interaction with Metal Ions and Small Molecules
  • 7 Density Functional Theory Calculations of Enzyme-Inhibitor Interactions in Medicinal Chemistry and Drug Design
  • 8 Molecular Dynamics Simulations of Lipid Bilayers with Incorporated Peptides
  • 9 Polyphenol Glycosides as Potential Remedies in Kidney Stones Therapy. Experimental Research Supported by Computational Studies
  • 10 Quantum-Chemical Investigation of Epoxidic Compounds Transformation. Application for In Vitro and In Vivo Processes Modeling
  • 11 Computational Toxicology in Drug Discovery: opportunities and limitations
  • 12 Consensus Drug Design Using it Microcosm
  • 13 Continuous Molecular Fields Approach Applied to Structure-Activity Modeling
  • 14 Quantitative Structure-Pharmacokinetic Relationships of Drugs within the Framework of Biopharmaceutics Classification System by Using Simplex Representation of Molecular Structure
  • 15 (How to) Profit from Molecular Dynamics-based Ensemble Docking
  • 16 Cheminformatics on Crossroad of Eras.
The current volume provides both fundamental and detailed information about the computational and computational-experimental studies which improve our knowledge of how leaving matter functions. It also covers research areas related to structures and properties of drugs (including the calculation and the design of new ones), and the development of completely new ways of treating numerical diseases. Whenever it is possible, the interplay between theory and experiment is emphasized. The book features computational techniques such as quantum-chemical and molecular dynamic approaches supplemented by a discussion on quantitative structure?activity relationships. The initial chapters describe the state-of-the art computational approaches for molecular biology, molecular pharmacy, and molecular medicine performed with the use of pure quantum-chemical techniques. The central part of the book illustrates the status of computational techniques that utilize hybrid, so called QM/MM approximations. In addition, the results of the QSAR studies, which now are the most popular in predicting drugs? efficiency, are discussed. The last chapter reveals the current state of chemoinformatics and discusses new problems and experimental perspectives related to both chemical and biological characteristics of molecules.
  • 1 Hybrid QM/MM Methods: Treating Electronic Phenomena in Very Large Molecular Systems
  • 2 Structure, Thermodynamics and Energetics of Drug-DNA Interactions: Computer Modeling and Experiment
  • 3 Formation of DNA Lesions, Its Prevention and Repair
  • 4 DNA dependent DNA Polymerases as Targets for Low-Weight Molecular Inhibitors: State of Art and Prospects of Rational Design
  • 5 Molecular structures, relative stability, and proton affinities of nucleotides: Broad view and novel findings
  • 6 Quantum Chemical Approaches in Modeling the Structure of Quadruplex DNA and Its Interaction with Metal Ions and Small Molecules
  • 7 Density Functional Theory Calculations of Enzyme-Inhibitor Interactions in Medicinal Chemistry and Drug Design
  • 8 Molecular Dynamics Simulations of Lipid Bilayers with Incorporated Peptides
  • 9 Polyphenol Glycosides as Potential Remedies in Kidney Stones Therapy. Experimental Research Supported by Computational Studies
  • 10 Quantum-Chemical Investigation of Epoxidic Compounds Transformation. Application for In Vitro and In Vivo Processes Modeling
  • 11 Computational Toxicology in Drug Discovery: opportunities and limitations
  • 12 Consensus Drug Design Using it Microcosm
  • 13 Continuous Molecular Fields Approach Applied to Structure-Activity Modeling
  • 14 Quantitative Structure-Pharmacokinetic Relationships of Drugs within the Framework of Biopharmaceutics Classification System by Using Simplex Representation of Molecular Structure
  • 15 (How to) Profit from Molecular Dynamics-based Ensemble Docking
  • 16 Cheminformatics on Crossroad of Eras.
The current volume provides both fundamental and detailed information about the computational and computational-experimental studies which improve our knowledge of how leaving matter functions. It also covers research areas related to structures and properties of drugs (including the calculation and the design of new ones), and the development of completely new ways of treating numerical diseases. Whenever it is possible, the interplay between theory and experiment is emphasized. The book features computational techniques such as quantum-chemical and molecular dynamic approaches supplemented by a discussion on quantitative structure?activity relationships. The initial chapters describe the state-of-the art computational approaches for molecular biology, molecular pharmacy, and molecular medicine performed with the use of pure quantum-chemical techniques. The central part of the book illustrates the status of computational techniques that utilize hybrid, so called QM/MM approximations. In addition, the results of the QSAR studies, which now are the most popular in predicting drugs? efficiency, are discussed. The last chapter reveals the current state of chemoinformatics and discusses new problems and experimental perspectives related to both chemical and biological characteristics of molecules.
Book
xii, 270 pages : illustrations (some color) ; 25 cm
  • States of matter related to pharmacuetical formulations / Beverly J. Sandmann, Ann Newman, and Gregory T. Knipp
  • Physical properties of solutions / Beverly Sandmann, Antoine Al-Achi, Robert Greenwood
  • Ionic equilibrium and buffers / Beverly Sandmann, Alekha K. Dash, Antoine Al-Achi, Robert Greenwood
  • Solubility, dissolution, and partitioning/ Beverly J. Sandmann and Mansoor M. Amiji
  • Mass transport / Mansoor M. Amiji
  • Complexation and protein binding / Mansoor M. Amiji
  • Dispersed systems / W. Cary Mobley
  • Interfacial phenomena / Maria Polikandritou Lambros and SHihong Li Nocolaou
  • Rheology / Maria Polikandritou Lambros
  • Chemical kinetics of pharmaceuticals / Thomas J. Cook.
  • States of matter related to pharmacuetical formulations / Beverly J. Sandmann, Ann Newman, and Gregory T. Knipp
  • Physical properties of solutions / Beverly Sandmann, Antoine Al-Achi, Robert Greenwood
  • Ionic equilibrium and buffers / Beverly Sandmann, Alekha K. Dash, Antoine Al-Achi, Robert Greenwood
  • Solubility, dissolution, and partitioning/ Beverly J. Sandmann and Mansoor M. Amiji
  • Mass transport / Mansoor M. Amiji
  • Complexation and protein binding / Mansoor M. Amiji
  • Dispersed systems / W. Cary Mobley
  • Interfacial phenomena / Maria Polikandritou Lambros and SHihong Li Nocolaou
  • Rheology / Maria Polikandritou Lambros
  • Chemical kinetics of pharmaceuticals / Thomas J. Cook.
Chemistry & ChemEng Library (Swain)
Status of items at Chemistry & ChemEng Library (Swain)
Chemistry & ChemEng Library (Swain) Status
Stacks
RS403 .A676 2014 Unknown
Book
1 online resource (vii, 237 pages) : illustrations (some color). Digital: text file; PDF.
  • Carbohydrate-Based Synthetic Chemistry in the Context of Drug Design
  • Iminosugars: Therapeutic Applications and Synthetic Considerations
  • Computational Docking as a Tool for the Rational Design of Carbohydrate-Based Drugs
  • Discovery and Development of Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Dapagliflozin for the Treatment of Type 2 Diabetes
  • Design, Synthesis, and Applications of Galectin Modulators in Human Health
  • Discovery and Application of FimH Antagonists
  • Carbohydrate-Based Anti-Virulence Compounds Against Chronic Pseudomonas aeruginosa Infections with a Focus on Small Molecules
  • The Evolution of a Glycoconjugate Vaccine for Candida albicans.
Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.
  • Carbohydrate-Based Synthetic Chemistry in the Context of Drug Design
  • Iminosugars: Therapeutic Applications and Synthetic Considerations
  • Computational Docking as a Tool for the Rational Design of Carbohydrate-Based Drugs
  • Discovery and Development of Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Dapagliflozin for the Treatment of Type 2 Diabetes
  • Design, Synthesis, and Applications of Galectin Modulators in Human Health
  • Discovery and Application of FimH Antagonists
  • Carbohydrate-Based Anti-Virulence Compounds Against Chronic Pseudomonas aeruginosa Infections with a Focus on Small Molecules
  • The Evolution of a Glycoconjugate Vaccine for Candida albicans.
Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.
Book
1 online resource (vii, 200 pages) : illustrations (some color).
  • Next Generation Sequencing: Chemistry, Technology and Applications, by P. Hui
  • Application of Next Generation Sequencing to Molecular Diagnosis of Inherited Diseases, by W. Zhang, H. Cui, L.-J.C. Wong
  • Clinical Applications of the Latest Molecular Diagnostics in Noninvasive Prenatal Diagnosis, by K.C.A. Chan
  • The Role of Protein Structural Analysis in the Next Generation Sequencing Era, by W.W. Yue, D.S. Froese, P.E. Brennan
  • Emerging Applications of Single-Cell Diagnostics, by M. Shirai, T. Taniguchi, H. Kambara
  • Mass Spectrometry in High-Throughput Clinical Biomarker Assays: Multiple Reaction Monitoring, by C.E. Parker, D. Domanski, A.J. Percy, A.G. Chambers, A.G. Camenzind, D.S. Smith, C.H. Borchers
  • Advances in MALDI Mass Spectrometry in Clinical Diagnostic Applications, by E.W.Y. Ng, M.Y.M. Wong, T.C.W. Poon
  • Application of Mass Spectrometry in Newborn Screening: About Both Small Molecular Diseases and Lysosomal Storage Diseases, by W.-L. Hwu, Y.-H. Chien, N.-C. Lee, S.-F. Wang, S.-C. Chiang, L.-W. Hsu.
  • Next Generation Sequencing: Chemistry, Technology and Applications, by P. Hui
  • Application of Next Generation Sequencing to Molecular Diagnosis of Inherited Diseases, by W. Zhang, H. Cui, L.-J.C. Wong
  • Clinical Applications of the Latest Molecular Diagnostics in Noninvasive Prenatal Diagnosis, by K.C.A. Chan
  • The Role of Protein Structural Analysis in the Next Generation Sequencing Era, by W.W. Yue, D.S. Froese, P.E. Brennan
  • Emerging Applications of Single-Cell Diagnostics, by M. Shirai, T. Taniguchi, H. Kambara
  • Mass Spectrometry in High-Throughput Clinical Biomarker Assays: Multiple Reaction Monitoring, by C.E. Parker, D. Domanski, A.J. Percy, A.G. Chambers, A.G. Camenzind, D.S. Smith, C.H. Borchers
  • Advances in MALDI Mass Spectrometry in Clinical Diagnostic Applications, by E.W.Y. Ng, M.Y.M. Wong, T.C.W. Poon
  • Application of Mass Spectrometry in Newborn Screening: About Both Small Molecular Diseases and Lysosomal Storage Diseases, by W.-L. Hwu, Y.-H. Chien, N.-C. Lee, S.-F. Wang, S.-C. Chiang, L.-W. Hsu.

8. Chemistry of drugs [2014]

Book
x, 260 p. : ill. ; 24 cm.
Chemistry & ChemEng Library (Swain)
Status of items at Chemistry & ChemEng Library (Swain)
Chemistry & ChemEng Library (Swain) Status
Stacks
RS403 .B27 2014 Unknown
Book
1 online resource (xv, 415 pages)
  • Preface vii Contributors xiii 1 What Are Our Models Really Telling Us? A Practical Tutorial onAvoiding Common Mistakes when Building Predictive Models 1 W. Patrick Walters 2 The Challenge of Creativity in Drug Design 33 Ajay N. Jain 3 A Rough Set Theory Approach to the Analysis of Gene ExpressionProfiles 51 Joachim Petit, Nathalie Meurice, Jose Luis Medina-Franco, and Gerald M. Maggiora 4 Bimodal Partial Least-Squares Approach and Its Application toChemogenomics Studies for Molecular Design 85 Kiyoshi Hasegawa and Kimito Funatsu 5 Stability in Molecular Fingerprint Comparison 97 Anthony Nicholls and Brian Kelley 6 C ritical Assessment of Virtual Screening for HitIdentification 113 Dagmar Stumpfe and Jurgen Bajorath 7 Chemometric Applications of Naive Bayesian Models in DrugDiscovery: Beyond Compound Ranking 131 Eugen Lounkine, Peter S. Kutchukian, and Meir Glick 8 Chemoinformatics in Lead Optimization 149 Darren V. S. Green and Matthew Segall 9 Using Chemoinformatics Tools to Analyze Chemical Arrays inLead Optimization 179 George Papadatos, Valerie J. Gillet, Christopher N. Luscombe, Iain M. McLay, Stephen D. Pickett, and Peter Willett 10 Exploration of Structure Activity Relationships (SAR s)and Transfer of Key Elements in Lead Optimization 205 Hans Matter, Stefan Gussregen, Friedemann Schmidt, GerhardHessler, Thorsten Naumann, and Karl-Heinz Baringhaus 11 Development and Applications of Global ADMET Models: InSilico Prediction of Human Microsomal Lability 245 Karl-Heinz Baringhaus, Gerhard Hessler, Hans Matter, andFriedemann Schmidt 12 Chemoinformatics and Beyond: Moving from Simple Models toComplex Relationships in Pharmaceutical Computational Toxicology267 Catrin Hasselgren, Daniel Muthas, Ernst Ahlberg, SamuelAndersson, Lars Carlsson, Tobias Noeske, Jonna Stalring, andScott Boyer 13 Applications of Cheminformatics in Pharmaceutical Research:Experiences at Boehringer Ingelheim in Germany 291 Bernd Beck, Michael Bieler, Peter Haebel, AndreasTeckentrup, Alexander Weber, and Nils Weskamp 14 Lessons Learned from 30 Years of Developing SuccessfulIntegrated Cheminformatic Systems 321 Michael S. Lajiness and Thomas R. Hagadone 15 Molecular Similarity Analysis 343 Jose L. Medina-Franco and Gerald M. Maggiora Index 401.
  • (source: Nielsen Book Data)
The first guide to address the strengths, weaknesses, case studies, and applications of cheminformatics approaches to drug discovery, Chemoinformatics addresses how these in silico techniques are applied in both academic and industrial research environments. Discussing approaches that have been successful as well as those that have not, the text outlines cheminformatics infrastructure tools and their implementation and describes the impact of different approaches on experimental or pharmaceutical research. A valuable resource for computational, medicinal/pharmaceutical scientists, chemical biologists, and computational biologists, the text includes case studies and applications by experimental and industrial researchers.
(source: Nielsen Book Data)
  • Preface vii Contributors xiii 1 What Are Our Models Really Telling Us? A Practical Tutorial onAvoiding Common Mistakes when Building Predictive Models 1 W. Patrick Walters 2 The Challenge of Creativity in Drug Design 33 Ajay N. Jain 3 A Rough Set Theory Approach to the Analysis of Gene ExpressionProfiles 51 Joachim Petit, Nathalie Meurice, Jose Luis Medina-Franco, and Gerald M. Maggiora 4 Bimodal Partial Least-Squares Approach and Its Application toChemogenomics Studies for Molecular Design 85 Kiyoshi Hasegawa and Kimito Funatsu 5 Stability in Molecular Fingerprint Comparison 97 Anthony Nicholls and Brian Kelley 6 C ritical Assessment of Virtual Screening for HitIdentification 113 Dagmar Stumpfe and Jurgen Bajorath 7 Chemometric Applications of Naive Bayesian Models in DrugDiscovery: Beyond Compound Ranking 131 Eugen Lounkine, Peter S. Kutchukian, and Meir Glick 8 Chemoinformatics in Lead Optimization 149 Darren V. S. Green and Matthew Segall 9 Using Chemoinformatics Tools to Analyze Chemical Arrays inLead Optimization 179 George Papadatos, Valerie J. Gillet, Christopher N. Luscombe, Iain M. McLay, Stephen D. Pickett, and Peter Willett 10 Exploration of Structure Activity Relationships (SAR s)and Transfer of Key Elements in Lead Optimization 205 Hans Matter, Stefan Gussregen, Friedemann Schmidt, GerhardHessler, Thorsten Naumann, and Karl-Heinz Baringhaus 11 Development and Applications of Global ADMET Models: InSilico Prediction of Human Microsomal Lability 245 Karl-Heinz Baringhaus, Gerhard Hessler, Hans Matter, andFriedemann Schmidt 12 Chemoinformatics and Beyond: Moving from Simple Models toComplex Relationships in Pharmaceutical Computational Toxicology267 Catrin Hasselgren, Daniel Muthas, Ernst Ahlberg, SamuelAndersson, Lars Carlsson, Tobias Noeske, Jonna Stalring, andScott Boyer 13 Applications of Cheminformatics in Pharmaceutical Research:Experiences at Boehringer Ingelheim in Germany 291 Bernd Beck, Michael Bieler, Peter Haebel, AndreasTeckentrup, Alexander Weber, and Nils Weskamp 14 Lessons Learned from 30 Years of Developing SuccessfulIntegrated Cheminformatic Systems 321 Michael S. Lajiness and Thomas R. Hagadone 15 Molecular Similarity Analysis 343 Jose L. Medina-Franco and Gerald M. Maggiora Index 401.
  • (source: Nielsen Book Data)
The first guide to address the strengths, weaknesses, case studies, and applications of cheminformatics approaches to drug discovery, Chemoinformatics addresses how these in silico techniques are applied in both academic and industrial research environments. Discussing approaches that have been successful as well as those that have not, the text outlines cheminformatics infrastructure tools and their implementation and describes the impact of different approaches on experimental or pharmaceutical research. A valuable resource for computational, medicinal/pharmaceutical scientists, chemical biologists, and computational biologists, the text includes case studies and applications by experimental and industrial researchers.
(source: Nielsen Book Data)
Book
xiii, 146 p. : ill. ; 24 cm
Chemistry & ChemEng Library (Swain)
Status of items at Chemistry & ChemEng Library (Swain)
Chemistry & ChemEng Library (Swain) Status
Stacks
RS407 .D53 2014 Unavailable At bindery Request
Book
xii, 385 p. : ill.
  • Generic Drug Product Development and Therapeutic Equivalence-- Leon Shargel and Isadore Kanfer Active Pharmaceutical Ingredients-- Edward M. Cohen and Steven Sutherland Analytical Methods Development and Methods Validation for Oral Solid Dosage Forms-- Quanyin Gao and Dilip R. Sanvordeker Experimental Formulation Development-- Isadore Kanfer, Roderick B. Walker, Raimar Lobenberg, and Nadia Araci Bou-Chacra Scale-up, Technology Transfer, and Process Performance Qualification-- Salah U. Ahmed, Ashok Katdare, Venkatesh Naini, and Dilip Wadgaonkar Drug Stability-- Pranab K. Bhattacharyya Quality Control and Quality Assurance-- Loren Gelber Drug Product Performance: In Vitro-- Pradeep M. Sathe, John Duan, and Lawrence X. Yu ANDA Regulatory Approval Process-- Timothy W. Ames and Aaron Sigler Bioequivalence and Drug Product Assessment: In Vivo-- Barbara M. Davit and Dale P. Conner Statistical Considerations for Establishing Bioequivalence-- Charles Bon and Sanford Bolton Outsourcing Bioavailability and Bioequivalence Studies to Contract Research Organizations-- Patrick K. Noonan Postapproval Changes and Postmarketing Reporting of Adverse Drug Experiences-- Lorien Armour and Leon Shargel The United States Pharmacopeia/National Formulary: Its History, Organization, and Role in Harmonization-- William Brown and Margareth R. C. Marques Legal and Legislative Hurdles to Generic Drug Development, Approval, and Marketing-- Arthur T. Tsien Index.
  • (source: Nielsen Book Data)
In this era of increased pharmaceutical industry competition, success for generic drug companies is dependent on their ability to manufacture therapeutic-equivalent drug products in an economical and timely manner, while also being cognizant of patent infringement and other legal and regulatory concerns. Generic Drug Product Development: Solid Oral Dosage Forms, Second Edition presents in-depth discussions from more than 30 noted specialists describing the development of generic drug products-from the raw materials to the development of a therapeutic-equivalent drug product to regulatory approval. Major topics discussed include: * Active pharmaceutical ingredients * Experimental formulation development, including a new section on Quality by Design (QbD) * Scale-up * Commercial product formulation * Quality control and bioequivalence * Drug product performance * ANDA regulatory process * Post-approval changes * Post-marketing surveillance * Legislative and patent challenges This second edition also contains a new chapter on the relationship between the FDA and the United States Pharmacopeia and in Chapter 4, using specific examples, the application of Quality by Design (QbD) during formulation development is examined.The book is a thorough guide to the development of solid oral generic dosage formulations. This textbook is ideal for the pharmaceutical industry, graduate programs in pharmaceutical sciences, and health professionals working in the area of generic drug development.
(source: Nielsen Book Data)
  • Generic Drug Product Development and Therapeutic Equivalence-- Leon Shargel and Isadore Kanfer Active Pharmaceutical Ingredients-- Edward M. Cohen and Steven Sutherland Analytical Methods Development and Methods Validation for Oral Solid Dosage Forms-- Quanyin Gao and Dilip R. Sanvordeker Experimental Formulation Development-- Isadore Kanfer, Roderick B. Walker, Raimar Lobenberg, and Nadia Araci Bou-Chacra Scale-up, Technology Transfer, and Process Performance Qualification-- Salah U. Ahmed, Ashok Katdare, Venkatesh Naini, and Dilip Wadgaonkar Drug Stability-- Pranab K. Bhattacharyya Quality Control and Quality Assurance-- Loren Gelber Drug Product Performance: In Vitro-- Pradeep M. Sathe, John Duan, and Lawrence X. Yu ANDA Regulatory Approval Process-- Timothy W. Ames and Aaron Sigler Bioequivalence and Drug Product Assessment: In Vivo-- Barbara M. Davit and Dale P. Conner Statistical Considerations for Establishing Bioequivalence-- Charles Bon and Sanford Bolton Outsourcing Bioavailability and Bioequivalence Studies to Contract Research Organizations-- Patrick K. Noonan Postapproval Changes and Postmarketing Reporting of Adverse Drug Experiences-- Lorien Armour and Leon Shargel The United States Pharmacopeia/National Formulary: Its History, Organization, and Role in Harmonization-- William Brown and Margareth R. C. Marques Legal and Legislative Hurdles to Generic Drug Development, Approval, and Marketing-- Arthur T. Tsien Index.
  • (source: Nielsen Book Data)
In this era of increased pharmaceutical industry competition, success for generic drug companies is dependent on their ability to manufacture therapeutic-equivalent drug products in an economical and timely manner, while also being cognizant of patent infringement and other legal and regulatory concerns. Generic Drug Product Development: Solid Oral Dosage Forms, Second Edition presents in-depth discussions from more than 30 noted specialists describing the development of generic drug products-from the raw materials to the development of a therapeutic-equivalent drug product to regulatory approval. Major topics discussed include: * Active pharmaceutical ingredients * Experimental formulation development, including a new section on Quality by Design (QbD) * Scale-up * Commercial product formulation * Quality control and bioequivalence * Drug product performance * ANDA regulatory process * Post-approval changes * Post-marketing surveillance * Legislative and patent challenges This second edition also contains a new chapter on the relationship between the FDA and the United States Pharmacopeia and in Chapter 4, using specific examples, the application of Quality by Design (QbD) during formulation development is examined.The book is a thorough guide to the development of solid oral generic dosage formulations. This textbook is ideal for the pharmaceutical industry, graduate programs in pharmaceutical sciences, and health professionals working in the area of generic drug development.
(source: Nielsen Book Data)
Book
xiv, 243 pages : illustrations (some color) ; 25 cm
  • Table of Contents -- Chapter 1: Seduced by drug discovery -- Chapter 2: The small molecules of life -- Chapter 3: Proteins: molecular wonders in three dimensions -- Chapter 4. Proteins perform multiple functions: enzymes, receptors, ion channels -- Chapter 5: Drug discovery and development: the road from an idea to promoting -- human health -- Chapter 6: Finasteride: the Gary and Jerry show -- Chapter 7: Basic research, snake venoms, and ACE inhibitors: Ondetti, Cushman, and -- Patchett -- Chapter 8: Statins: protection against heart attacks and strokes -- Chapter 9: The perils of Primaxin -- Chapter 10: Avermectins: molecules of life battle parasites -- Chapter 11: Fludalanine: nice try but no hallelujah -- Chapter 12: Diabetes Breakthrough: Januvia and Janumet.
  • (source: Nielsen Book Data)
Pharmeceutical drug discovery has wide-reaching and obvious effects on the lives of people everywhere, and yet the general public knows very little about the way in which these important products are conceived. We rely on pharmaceuticals to keep us healthy in countless ways, with almost no understanding of the process behind the creation of the drugs we use. in Hallelujah Moments, Eugene Cordes reveals just how some of the most important and influential drugs are made. He shares his firsthand knowledge of the drug-discovery world, having spent a long and distinguished career on both the academic and industrial side of pharmaceutical research. These tales are "adventure stories, " and they follow important drugs like Proscar, Capoten, and Mevacor from the idea stage all the way to the point of being made publicly available. Cordes shows us the dynamic and critical thinking needed to create a useful drug, and the human stories of risk-taking, problem-solving, and, in many cases, failure. Written accessibly for a non-scientist audience, Hallelujah Moments brings the general public up to speed on the fascinating world of drug discovery like never before.
(source: Nielsen Book Data)
  • Table of Contents -- Chapter 1: Seduced by drug discovery -- Chapter 2: The small molecules of life -- Chapter 3: Proteins: molecular wonders in three dimensions -- Chapter 4. Proteins perform multiple functions: enzymes, receptors, ion channels -- Chapter 5: Drug discovery and development: the road from an idea to promoting -- human health -- Chapter 6: Finasteride: the Gary and Jerry show -- Chapter 7: Basic research, snake venoms, and ACE inhibitors: Ondetti, Cushman, and -- Patchett -- Chapter 8: Statins: protection against heart attacks and strokes -- Chapter 9: The perils of Primaxin -- Chapter 10: Avermectins: molecules of life battle parasites -- Chapter 11: Fludalanine: nice try but no hallelujah -- Chapter 12: Diabetes Breakthrough: Januvia and Janumet.
  • (source: Nielsen Book Data)
Pharmeceutical drug discovery has wide-reaching and obvious effects on the lives of people everywhere, and yet the general public knows very little about the way in which these important products are conceived. We rely on pharmaceuticals to keep us healthy in countless ways, with almost no understanding of the process behind the creation of the drugs we use. in Hallelujah Moments, Eugene Cordes reveals just how some of the most important and influential drugs are made. He shares his firsthand knowledge of the drug-discovery world, having spent a long and distinguished career on both the academic and industrial side of pharmaceutical research. These tales are "adventure stories, " and they follow important drugs like Proscar, Capoten, and Mevacor from the idea stage all the way to the point of being made publicly available. Cordes shows us the dynamic and critical thinking needed to create a useful drug, and the human stories of risk-taking, problem-solving, and, in many cases, failure. Written accessibly for a non-scientist audience, Hallelujah Moments brings the general public up to speed on the fascinating world of drug discovery like never before.
(source: Nielsen Book Data)
SAL1&2 (on-campus shelving)
Status of items at SAL1&2 (on-campus shelving)
SAL1&2 (on-campus shelving) Status
Stacks Request
RM301.25 .C67 2014 Unknown
Book
1 online resource (ix, 326 pages) : illustrations (some color).
  • 1 Hydrophilic Matrix Dosage Forms: Definitions, General Attributes and the Evolution of Clinical Utilization
  • 2 Design and Evaluation of Hydroxypropyl Methylcellulose Matrix Tablets for Oral Controlled Release: a Historical Perspective
  • 3 An Industrial Perspective on Hydrophilic Matrix Tablets based on Hyproxypropyl Methylcellulose (Hypromellose)
  • 4 Natural Polysaccharides in Hydrophilic Matrices
  • 5 Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices
  • 6 A Formulation Development Perspective on Critical Interactions Affecting the Performance of Hydrophilic Matrix Tablets
  • 7 In vitro Physical and Imaging Techniques to Evaluate Drug Release Mechanisms from Hydrophilic Matrix Tablets
  • 8 Physiologically-Based Pharmacokinetic Modelling in the Development and Evaluation of Hydrophilic Matrix Tablets
  • 9 Approaches to Rapid In Vivo Optimization of Hydrophilic Matrix Tablets
  • 10 Extrusion: an Enabling Technology for Controlled Release Hydrophilic Matrix Systems
  • 11 Microenvironmental pH Control and Mixed Polymer Approaches to Optimize Drug Delivery with Hydrophilic Matrix Tablets
  • 12 Evolving Biopharmaceutics Perspectives for Hydrophilic Matrix Tablets: Dosage Form-Food Interactions and Dosage Form Gastrointestinal Tract Interactions.
  • 1 Hydrophilic Matrix Dosage Forms: Definitions, General Attributes and the Evolution of Clinical Utilization
  • 2 Design and Evaluation of Hydroxypropyl Methylcellulose Matrix Tablets for Oral Controlled Release: a Historical Perspective
  • 3 An Industrial Perspective on Hydrophilic Matrix Tablets based on Hyproxypropyl Methylcellulose (Hypromellose)
  • 4 Natural Polysaccharides in Hydrophilic Matrices
  • 5 Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices
  • 6 A Formulation Development Perspective on Critical Interactions Affecting the Performance of Hydrophilic Matrix Tablets
  • 7 In vitro Physical and Imaging Techniques to Evaluate Drug Release Mechanisms from Hydrophilic Matrix Tablets
  • 8 Physiologically-Based Pharmacokinetic Modelling in the Development and Evaluation of Hydrophilic Matrix Tablets
  • 9 Approaches to Rapid In Vivo Optimization of Hydrophilic Matrix Tablets
  • 10 Extrusion: an Enabling Technology for Controlled Release Hydrophilic Matrix Systems
  • 11 Microenvironmental pH Control and Mixed Polymer Approaches to Optimize Drug Delivery with Hydrophilic Matrix Tablets
  • 12 Evolving Biopharmaceutics Perspectives for Hydrophilic Matrix Tablets: Dosage Form-Food Interactions and Dosage Form Gastrointestinal Tract Interactions.
Book
1 online resource (xiii, 119 pages) : illustrations.
The book addresses the interdisciplinary scientific approach for the systemic understanding of connections between major human diseases and their treatment regime by applying the tools and techniques of nanotechnology. It also highlights the interdisciplinary collaborative researches for innovation in Biomedical Sciences. The book is a first volume which presents collection of best papers presented in the First International Conference on Infectious Diseases and Nanomedicine held during Dec. 15-18, 2012 in Kathmandu, Nepal. The book focuses mainly on the topics: emerging infectious diseases; antimicrobial agents, vaccines and immunity; drug design, drug delivery and tissue engineering; and nanomaterials and biomedical materials.
The book addresses the interdisciplinary scientific approach for the systemic understanding of connections between major human diseases and their treatment regime by applying the tools and techniques of nanotechnology. It also highlights the interdisciplinary collaborative researches for innovation in Biomedical Sciences. The book is a first volume which presents collection of best papers presented in the First International Conference on Infectious Diseases and Nanomedicine held during Dec. 15-18, 2012 in Kathmandu, Nepal. The book focuses mainly on the topics: emerging infectious diseases; antimicrobial agents, vaccines and immunity; drug design, drug delivery and tissue engineering; and nanomaterials and biomedical materials.
Book
1 online resource (xv, 61 pages) : illustrations (some color).
Book
1 online resource.
Book
xiii, 418 p. : ill. ; 26 cm.
  • 1 A Brief History of Drug Discovery 2 The Modern Drug Process 3 A Trip through the Body 4 Enzymes as Drug Targets 5 Receptors as Drug Targets 6 Oligonucleotides as Drug Targets 7 Pharmacokinetics 8 Metaboism 9 Molecular Structure and Diversity 10 Lead Discovery 11 Lead Optimization- Traditional Methods 12 Lead Optimization- Hansch Analysis 13 Aspects in Pharmaceutical Synthesis.
  • (source: Nielsen Book Data)
Emphasizing applications of chemistry while reinforcing theory - especially in the areas of organic and physical chemistry - this new text prepares readers for career success in the pharmaceutical, medical, and biotech industries. Medicinal Chemistry: The Modern Drug Discovery Process delivers a comprehensive introduction to medicinal chemistry at an appropriate level of detail for a diverse range of readers. By highlighting the concepts and skills related to drug discovery, Stevens deepens readers' understanding of the knowledge and techniques necessary for their careers.
(source: Nielsen Book Data)
  • 1 A Brief History of Drug Discovery 2 The Modern Drug Process 3 A Trip through the Body 4 Enzymes as Drug Targets 5 Receptors as Drug Targets 6 Oligonucleotides as Drug Targets 7 Pharmacokinetics 8 Metaboism 9 Molecular Structure and Diversity 10 Lead Discovery 11 Lead Optimization- Traditional Methods 12 Lead Optimization- Hansch Analysis 13 Aspects in Pharmaceutical Synthesis.
  • (source: Nielsen Book Data)
Emphasizing applications of chemistry while reinforcing theory - especially in the areas of organic and physical chemistry - this new text prepares readers for career success in the pharmaceutical, medical, and biotech industries. Medicinal Chemistry: The Modern Drug Discovery Process delivers a comprehensive introduction to medicinal chemistry at an appropriate level of detail for a diverse range of readers. By highlighting the concepts and skills related to drug discovery, Stevens deepens readers' understanding of the knowledge and techniques necessary for their careers.
(source: Nielsen Book Data)
Chemistry & ChemEng Library (Swain)
Status of items at Chemistry & ChemEng Library (Swain)
Chemistry & ChemEng Library (Swain) Status
Stacks
RS403 .S745 2014 Unknown
Book
1 online resource.
  • Introduction
  • Lead discovery and lead modification
  • Receptors
  • Enzymes
  • Enzyme inhibition and inactivation
  • Dna-interactive agents
  • Drug resistance and drug synergism
  • Drug metabolism
  • Prodrugs and drug delivery systems.
The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage. New to this edition: * Updates to all chapters, including new examples and references* Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book* Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry* Chapter 3 (Receptors): Drug-receptor interactions, cation-? and halogen bonding; atropisomers; case history of the insomnia drug suvorexant* Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis* Chapter 5 (Enzyme Inhibition and Inactivation): New case histories: * for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib* for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid* for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin* Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples* Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites* Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody-drug conjugates.
(source: Nielsen Book Data)
  • Introduction
  • Lead discovery and lead modification
  • Receptors
  • Enzymes
  • Enzyme inhibition and inactivation
  • Dna-interactive agents
  • Drug resistance and drug synergism
  • Drug metabolism
  • Prodrugs and drug delivery systems.
The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage. New to this edition: * Updates to all chapters, including new examples and references* Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book* Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry* Chapter 3 (Receptors): Drug-receptor interactions, cation-? and halogen bonding; atropisomers; case history of the insomnia drug suvorexant* Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis* Chapter 5 (Enzyme Inhibition and Inactivation): New case histories: * for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib* for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid* for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin* Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples* Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites* Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody-drug conjugates.
(source: Nielsen Book Data)

Looking for different results?

Modify your search: Search all fields

Search elsewhere: Search WorldCat Search library website